ARTICLE | Clinical News
FDA grants breakthrough therapy designation to setmelanotide for obesity
May 19, 2017 12:20 AM UTC
Rhythm Holding Co. LLC (Boston, Mass.) said FDA granted breakthrough therapy designation to setmelanotide (RM-493) to treat obesity associated with genetic defects upstream of the melanocortin 4 receptor (MC4R) in the leptin-melanocortin pathway, including leptin receptor (LEPR; CD295) deficiency obesity...
BCIQ Target Profiles